You describe your research once. The most relevant new papers arrive each morning, summarized so you know what to read. Here’s what happens in between.
Each stage narrows the field until only the most relevant papers remain.
0+ papers
Indexed from every major scientific database
Candidates retrieved
Matched to your research profile
Unified
One entry per paper, across every source
Examined
Each paper read against your research
Selected
Best across multiple measures
Your top 3
Each one summarized
You describe your research once: what you’re working on, the methods you use, the questions you’re asking.
From your description, we build a research fingerprint of your work.
That profile drives more than a dozen searches across your field and beyond, reaching into adjacent domains where your next breakthrough might be published.
Your Research
“Investigating LRRK2 kinase inhibition as a therapeutic target for Parkinson’s disease using iPSC-derived dopaminergic neurons and mitochondrial functional assays...”
Every day, thousands of new papers are pulled from the largest scientific databases into a single corpus. If it was published in the last two weeks, it’s here.
0+
New papers every day
14
Day rolling window
Unified Corpus
100K+
Unique papers
Traditional search engines match keywords. Our approach reads your full research description alongside each paper’s title and abstract, scoring how precisely the two actually relate. It was chosen after blind evaluation across thousands of research projects.
Traditional Search
Keyword-matched, ranked by recency
Our Approach
Ranked by relevance to your research
Relevance alone isn’t enough. A paper can be on-topic but offer nothing new, or use interesting methods but lack evidence. Finalists pass through additional checks before the cut. What lands in your inbox is shorter than this paragraph.
What lands in your inbox
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
Nature Medicine · Apr 2026
The finding
Intrathecal BIIB094, an LRRK2-targeting antisense oligonucleotide, lowered cerebrospinal fluid LRRK2 by up to 59% and phosphorylated Rab10 by up to 50% across 82 Parkinson’s participants, irrespective of LRRK2 variant status, with no serious drug-related adverse events.
Every component you see above was chosen after hand-graded evaluation on real research projects across every major discipline.
1,000+
Projects evaluated
Pairwise, blinded reads
100+
Controlled experiments
One variable at a time
3
Papers in your inbox each morning
From 14 days of new science
Built for every field. Validated across all of them.